loading...| Preferred Name |
avanafil |
|
| Synonyms |
|
|
| Definitions |
An orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, thereby prolonging penile erection. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C74354" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74354" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000683134 |
|
| CAS Registry |
330784-47-9 |
|
| cui |
C2698280 |
|
| DATE FIRST PUBLISHED |
2010-08-04 |
|
| Date last modified |
2010-12-28 |
|
| definition |
An orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, thereby prolonging penile erection. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C74354" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74354" NCI Thesaurus) |
|
| NCI ID |
C74354 |
|
| notation |
CDR0000683134 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
avanafil |
|
| tui |
T109 T121 |